Advertisement

International Urology and Nephrology

, Volume 51, Issue 12, pp 2243–2254 | Cite as

High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents

  • Ahmed Yahia Elmowafy
  • Hanzada Mohamed El Maghrabi
  • Mohamed Elsayed Mashaly
  • Khaled Farouk Eldahshan
  • Lionel RostaingEmail author
  • Mohamed Adel Bakr
Nephrology - Original Paper

Abstract

Background

Direct-acting antivirals (DAAs) have significantly improved the efficacy and safety of treating chronic hepatitis C (CHC), but their effectiveness and safety among patients with chronic kidney disease (CKD) remains poorly understood. Sofosbuvir/daclatasvir regimen is supposed to be used for patients with creatinine clearance more than 30 mL/min, while ombitasvir/paritaprevir/ritonavir regimen is used for patients with creatinine clearance less than 30 mL/min.

Aim

The aim of the study was to assess the safety and efficacy of DAAs among patients with CKD.

Methods

Eighteen CKD stage 2–3b patients received sofosbuvir for 3 months. In addition, 42 CKD stage-4 patients received ritonavir-boosted paritaprevir plus ombitasvir for 3 months. Finally, ribavirin was added for 30 of them.

Results

The patients’age was 49.2 ± 12 years. Baseline serum creatinine was 3.76 ± 1.67 mg/dL. Fifty patients were HCV genotype 4. A 3-month sustained viral response was achieved in 56 patients and 49 patients achieved a 6-month viral response. There were 11 relapsers. Acute kidney injury (AKI) upon CKD (AKI/CKD) occurred in 28 patients, of which 20 needed hemodialysis. Fifteen/28 recovered from AKI, whereas 13 were maintained on hemodialysis. In multivariate analysis, there were only two independent risk factors for developing AKI/CKD, i.e., being cirrhotic as defined by baseline abdominal ultrasound findings [odds ratio 4.15 (1.33–12.97); p = 0.013] and having had as DAA therapy OMV/PTV/RTV [odds ratio 7.35 (1.84–29.35); p = 0.001].

Conclusion

Treatment of HCV among stage 2, 3a, and 3b patients was achieved safely with a sofosbuvir-based regimen. We recommend that stage-4 patients wait until starting hemodialysis or transplantation.

Keywords

Chronic kidney disease HCV infection Sofosbuvir Daclatasvir Acute renal failure DAA therapy 

Notes

Acknowledgements

The authors acknowledge the HCV working group (Urology and Nephrology teams), Egyptian Liver Research Institute team and Egyptian Medical Insurance System for supplying the DAAs.

Author contributions

AYE wrote the paper, HMEM and MEM helped in data collection, KFE followed up regarding hemodialysis; the work was under supervision of MAB and he reviewed the article. LR reviewed and finalized the paper.

Funding

Not funded. Mansoura Urology and Nephrology Center supported the immunosuppressive drugs and full laboratory and radiology investigations for the patients. Egyptian Liver Research Institute and Hospital afforded the direct antiviral in collaboration with Egyptian Health Insurance System.

Compliance with ethical standards

Conflict of interest

All authors declare no conflict of interest.

References

  1. 1.
    Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D (2015) Management of patients with hepatitis C infection and renal disease. World J Hepatol 7:213–225CrossRefGoogle Scholar
  2. 2.
    Polaris Observatory HCV Collaborators (2016) Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2:161–176Google Scholar
  3. 3.
    Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C (2016) Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol 65:S82–S94CrossRefGoogle Scholar
  4. 4.
    Fabrizi F, Dixit V, Martin P, Messa P (2012) The evidence-based epidemiology of HCV-associated kidney disease. Int J Artif Organs 35:621–628CrossRefGoogle Scholar
  5. 5.
    Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z (2015) A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat 22:897–905CrossRefGoogle Scholar
  6. 6.
    Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, O’Hare AM (2007) Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 167:1271–1276CrossRefGoogle Scholar
  7. 7.
    Fabrizi F, Dixit V, Messa P, Martin P (2014) Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. J Viral Hepat 21:681–689CrossRefGoogle Scholar
  8. 8.
    Ladino M, Pedraza F, Roth D (2016) Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol 27:2238–2246CrossRefGoogle Scholar
  9. 9.
    Reese PP, Abt PL, Blumberg EA, Goldberg DS (2015) Transplanting hepatitis C-positive kidneys. N Engl J Med 373:303–305CrossRefGoogle Scholar
  10. 10.
    Lubetzky M, Chun S, Joelson A, Coco M, Kamal L, Ajaimy M, Gaglio P, Akalin E, De Boccardo G (2017) Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents. Transplantation 101:1704–1710CrossRefGoogle Scholar
  11. 11.
    Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssière L, Esposito L, Del Bello A, Métivier S, Barange K, Izopet J, Alric L (2016) Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant 16:1474–1479CrossRefGoogle Scholar
  12. 12.
    Fabrizi F, Martin P, Messa P (2016) New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int 89:988–994CrossRefGoogle Scholar
  13. 13.
    Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NAHCV-TARGET (2016) Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36:807–816CrossRefGoogle Scholar
  14. 14.
    American Association for the study of Liver Disease/Infectious Disease Society of America/International Antiviral Society (2015) Recommendations for testing, managing, and treating hepatitis C virus. Updated 7 Aug 2015. http://www.hcvguidelines.org. Accessed 5 Jan 2016
  15. 15.
    Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L Jr, Hu YB, Podsadecki T, Bernstein B (2014) ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147(359–365):e1Google Scholar
  16. 16.
    Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B (2014) Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 370:222–232CrossRefGoogle Scholar
  17. 17.
    Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S (2015) Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomized, open-label trial. Lancet 385:2502–2509CrossRefGoogle Scholar
  18. 18.
    Jahangiri F, Hooman N (2015) Results and complications of children with ESRD undergoing peritoneal dialysis catheter placement 1997–2013 in Aliasghar Pediatric Hospital. J Pediatr Nephrol Winter Suppl 1:1Google Scholar
  19. 19.
    Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein D, Podsadecki T, Cohen D, Shulman NS, Wang D, Khatri A, Abunimeh M, Lawitz E (2015) Safety of ombitasvir/paritaprevir/ritonavir + dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study. EASL 2015. J Hepatol 62:S257 (Abstract LO1) CrossRefGoogle Scholar
  20. 20.
    Muñoz-Gómez R, Rincón D, Ahumada A, Hernández E, Devesa MJ, Izquierdo S, Ortiz M, Hernández-Albujar A, Fernández-Rodríguez C, Calvo M, González R, Lozano M, Castellano G, Fernández-Vázquez I (2017) Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: a multicentre experience. J Viral Hepat 24:464–467CrossRefGoogle Scholar
  21. 21.
    Sise ME, Backman E, Ortiz GA, Hundemer GL, Ufere NN, Chute DF, Brancale J, Xu D, Wisocky J, Lin MV, Kim AY, Thadhani R, Chung RT (2017) Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD. Clin J Am Soc Nephrol 12:1615–1623CrossRefGoogle Scholar
  22. 22.
    Bernstein DE, Tran A, Martin P, Kowdley KV, Bourliere M, Sulkowski MS, Pockros PJ, Renjifo B, Wang D, Shuster DL, Cohen DE, Jacobson IM (2018) Ombitasvir, paritaprevir, ritonavir, and dasabuvir with or without ribavirin in patients with kidney disease. Kidney Int Rep 4:245–256CrossRefGoogle Scholar
  23. 23.
    Manoj K, Nayak SL, Gupta E, Kataria A, Sarin SK (2018) Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease. Liver Int 38:2137–2148CrossRefGoogle Scholar
  24. 24.
    Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM (2016) Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment. Drug Saf 39:589–611CrossRefGoogle Scholar
  25. 25.
    Desnoyer A, Pospai D, Lê MP, Gervais A, Heurgué-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, Fontaine H, Zucman D, Simonpoli AM, Muret P, Larrouy L, Bernard Chabert B, Descamps D, Yazdanpanah Y, Peytavin G (2016) Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 65:40–47CrossRefGoogle Scholar
  26. 26.
    Shuster DL, Menon RM, Ding B, Khatri A, Li H, Cohen E, Jewett M, Cohen DE, Zha J (2019) Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials. Eur J Clin Pharmacol 75:207–216CrossRefGoogle Scholar
  27. 27.
    Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T (2018) Daclatasvir: a review of preclinical and clinical pharmacokinetics. Clin Pharmacokinet 57:911–928CrossRefGoogle Scholar
  28. 28.
    Sorbera MA, Friedman ML, Cope R (2017) New and emerging evidence on the use of second-generation direct acting antivirals for the treatment of hepatitis C virus in renal impairment. J Pharm Pract 30:359–365CrossRefGoogle Scholar
  29. 29.
    European Association for Study of Liver (2015) EASL Recommendations on treatment of hepatitis C 2015. J Hepatol 63:199–236.  https://doi.org/10.1016/j.jhep.2015.03.025 CrossRefGoogle Scholar
  30. 30.
    Dumortier J, Bailly F, Pageaux GP, Vallet-Pichard A, Radenne S, Habersetzer F, Gagnieu MC, Grangé JD, Minello A, Guillaud O, Kamar N, Alric L, Leroy V (2017) Sofosbuvir-based Antiviral therapy in hepatitis C virus patients with severe renal failure. Nephrol Dial Transplant 32:2065–2071PubMedGoogle Scholar
  31. 31.
    Gane E, Sola R, Cohen E, Roberts SK, George J, Skoien R, Riordan S, Mobashery N, Abunimeh M, Cohen DE, Agarwal K (2016) RUBY-II: efficacy and safety of a ribavirin-free ombitasvir/paritaprevir/ritonavir ± dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV genotype 1a or 4 infection. AASLD 2016. Hepatology 64:361–601 (Abstract 935) Google Scholar
  32. 32.
    Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Asano T, Yoshizawa K, Okubo T, Chuganji Y, Aizawa Y, Iio E, Tanaka Y, Iwakiri K (2017) Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatol Res 47:1165–1173CrossRefGoogle Scholar
  33. 33.
    Willemse SB, Baak LC, Kuiken SD, van der Sluys Veer A, Lettinga KD, van der Meer JT, Depla AC, Tuynman H, van Nieuwkerk CM, Schinkel CJ, Kwa D, Reesink HW, van der Valk M (2016) Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life. J Viral Hepat 23:950–954CrossRefGoogle Scholar
  34. 34.
    Ahmed OA, Elsebaey MA, Fouad MHA, Elkadeem M, Badawi R, Khayyal A, Soliman S, Negm MS, Abd-Elsalam S (2018) Outcomes of treatment and predictors of response to sofosbuvir plus simeprevir in hepatitis c virus with genotype-4 infection. Infect Disord Drug Targets.  https://doi.org/10.2174/1871526519666181218104600 CrossRefPubMedGoogle Scholar
  35. 35.
    Di Biagio A, Taramasso L, Cenderello G (2018) Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J 15:180CrossRefGoogle Scholar
  36. 36.
    Ridruejo E, Mendizabal M, Silva MO (2018) Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease. Hemodial Int 22:S97–S103CrossRefGoogle Scholar
  37. 37.
    Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, Stättermayer AF, Stauber R, Strasser M, Zoller H, Watschinger B, Schmidt A, Trauner M, Hofer H, Maieron A (2016) DAA-based antiviral treatment of patients with chronic hepatitis C in the pre-and postkidney transplantation setting. Transpl Int 29:999–1007CrossRefGoogle Scholar
  38. 38.
    Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, François C (2010) Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther 15:687–695CrossRefGoogle Scholar
  39. 39.
    Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B (2014) Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1594–1603CrossRefGoogle Scholar
  40. 40.
    Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B (2014) Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1604–1614CrossRefGoogle Scholar
  41. 41.
    Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T, Bernstein B, Awni W, Menon R (2015) Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 15(5):1313–1322.  https://doi.org/10.1111/ajt.13111(epub 2015 Feb 23) CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Mansour M, Hill L, Kerr J (2018) Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation. Transpl Infect Dis. 20(6):e12972.  https://doi.org/10.1111/tid.12972(epub 2018 Aug 22) CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Urology and Nephrology CenterMansoura UniversityMansouraEgypt
  2. 2.Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation RénaleCHU Grenoble-AlpesGrenoble Cedex 09France
  3. 3.Université Grenoble AlpesGrenobleFrance
  4. 4.Nephrology DepartmentPort-Said UniversityPort FuadEgypt

Personalised recommendations